Ensysce Biosciences ended Q2 2026 with only $676,704 of cash and equivalents, but its liquidity position changed substantially immediately after quarter-end as the acquisition of Cy Biopharma and related financings provided approximately $31 million of net cash after transaction expenses.
The financing associated with the transaction totaled $38.6 million before transaction expenses. Cy Biopharma brought $17.1 million of cash from a pre-acquisition convertible-note financing, while Ensysce simultaneously agreed to sell Series C non-voting convertible preferred stock for approximately $21.5 million of gross proceeds.
Another $38.6 million financing tranche could become available if it achieves specified clinical milestones. Management said the initial financing provides cash runway into late 2027, while the second tranche could extend the company’s runway into 2028.
The before-and-after liquidity contrast is particularly significant because Ensysce used approximately $5.46 million of operating cash during the first half of 2026, more than eight times its June 30 cash balance. Cash had declined from $4.31 million at the end of 2025.
The acquisition also changed Ensysce’s pipeline priorities. Cy Biopharma brought CY200, a clinical-stage neuroplastogenic candidate for Complex Regional Pain Syndrome Type 1, which has FDA Orphan Drug Designation and is now positioned as the company’s lead asset.
Ensysce intends to use proceeds from the private placements primarily to advance CY200 through a randomized Phase 2 trial evaluating efficacy, safety and tolerability and to prepare the program for potential registrational development. The company noted that no therapy is currently approved for CRPS.
The transaction therefore represents more than a balance-sheet recapitalization. The financing is directly tied to a shift in Ensysce’s clinical strategy toward a newly acquired lead program while the company continues advancing its existing opioid portfolio.
One of those existing programs is PF614, an extended-release oxycodone candidate designed with Trypsin-Activated Abuse Protection technology. Development continues through the pivotal PF614-301 Phase 3 study, which evaluates the product for moderate-to-severe pain following abdominoplasty.
PF614-MPAR combines the TAAP platform with the company’s Multi-Pill Abuse Resistance technology and has received FDA Breakthrough Therapy designation. Ensysce continued enrolling subjects in the PF614-MPAR-102 study during the quarter.
Federal funding is helping offset part of that development expense. Ensysce had $5.3 million remaining through May 2027 under a $15.1 million National Institute on Drug Abuse grant, and management said NIDA has provided two major awards totaling more than $26 million over six years to support its overdose-protection work.
Clinical investment increased before the Cy transaction. Q2 R&D expense rose to $2.47 million from $1.92 million, primarily because of higher external research and development spending associated with PF614. First-half R&D expense increased to $5.82 million from $3.81 million.
The higher spending contributed to a wider loss. Q2 net loss attributable to common shareholders increased to $2.57 million from $1.73 million, while the first-half net loss widened to $6.13 million from $3.68 million.
Ensysce’s post-quarter financing therefore materially changes the company’s ability to fund development compared with its June 30 balance sheet. The immediate approximately $31 million cash addition supports CY200 and other programs into late 2027, while the potential milestone-triggered second tranche could add another $38.6 million if clinical development advances as required.
KEY QUOTES:
“Cy Biopharma’s neuroplastogenic approach to complex pain was the most compelling strategic opportunity we explored, and we believe this acquisition represents a significant value creation opportunity for Ensysce stockholders. The concurrent private placement financing was intentionally sized to support our immediate strategic objectives while maintaining financial discipline and allow us to progress our lead candidate in a pain market valued over $1 billion for which there is currently no approved therapy,”
“During the second quarter of 2026 we also advanced the clinical development of PF614-MPAR, the first opioid engineered with built-in overdose protection. To support this clinical development, we were awarded the third year of funding under a $15.1 million grant from the National Institute on Drug Abuse (NIDA), completing the award, a powerful vote of confidence from a leading federal agency that has backed this program with two major awards totaling over $26 million over six years.”
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences
